Axial Spondyloarthritis Market Size, Growth and Forecast 2032

Axial Spondyloarthritis Market

The global Axial Spondyloarthritis Market size was estimated at USD 6,707.16 million in 2025 and is expected to reach USD 9,066.55 million by 2032, growing at a CAGR of 4.4% from 2025 to 2032. Demand expansion is being driven primarily by earlier and more confident diagnosis of inflammatory back pain combined with wider use of targeted therapies that improve disease control versus symptom-only management. Over the forecast period, broader access pathways for advanced therapies and strengthening specialist care capacity in developed markets are expected to keep treatment rates rising in both radiographic and non-radiographic disease.

Key Market Trends & Insights

• The market is projected to expand from USD 6,707.16 million to USD 9,066.55 million at a 4.4% CAGR (2025–2032).
• Radiographic axial spondyloarthritis / ankylosing spondylitis remains the leading disease type with 65.7% share.
• Conventional DMARDs / other therapies account for the largest drug-class share at 48.3%.
• Injectable / subcutaneous therapies lead by route with 46.4% share, supported by established biologic usage.
• North America represents the largest regional revenue share at 35.62%, reflecting higher diagnosis and biologic access intensity.

Segment Analysis

Clinical practice is shifting toward earlier identification of axial spondyloarthritis, which expands the treated population beyond patients with long-standing radiographic damage. Shorter diagnostic pathways supported by imaging and clearer classification criteria increase initiation rates of disease-modifying treatment, particularly for patients who previously cycled through symptomatic care. This shift increases demand for biologics and targeted synthetics, and it also improves persistence when patients experience measurable symptom control and functional improvement.

Therapy choice is increasingly influenced by convenience and payer rules. Subcutaneous biologics remain central due to entrenched clinician experience and patient-support programs, but oral options are gaining attention for patients prioritizing ease of administration and fewer clinic visits. At the same time, biosimilar-driven price competition and step-therapy policies are shaping sequencing across TNF, IL-17, and newer targeted options, reinforcing the need for differentiated efficacy, tolerability, and long-term response durability.

By Disease Type Insights

Radiographic Axial Spondyloarthritis / Ankylosing Spondylitis accounted for the largest share of 65.7% in 2025. It leads because radiographic disease has clearer diagnostic confirmation and more established treatment pathways, which accelerates therapy initiation. Clinicians also have deeper experience managing ankylosing spondylitis with biologics, supporting confident escalation after NSAID failure. Over time, earlier referral patterns and better imaging access continue to lift treatment intensity, sustaining the segment’s revenue contribution.

By Drug Class Insights

Conventional DMARDs / Other Therapies accounted for the largest share of 48.3% in 2025. This category benefits from its role in foundational management alongside NSAIDs and its relevance in broader inflammatory disease pathways where overlap conditions are treated. Treatment algorithms also drive consistent utilization of non-biologic options before and alongside advanced therapies in many markets. Pricing accessibility, familiarity, and formulary positioning reinforce volume, even as targeted agents gain share in higher-severity or refractory patients.

By Route of Administration Insights

Injectable / Subcutaneous accounted for the largest share of 46.4% in 2025. The route is anchored by long-established biologic delivery models, which are supported by home-administration training, patient-support services, and predictable adherence routines. Self-injectables also reduce infusion-center dependency and can lower non-drug administration burden. As more patients start biologics earlier in the disease journey, subcutaneous use remains a core modality for ongoing maintenance therapy.

By Distribution Channel Insights

Hospital Pharmacies accounted for the largest share of 42.2% in 2025. Initiation and early monitoring are commonly tied to specialist-led hospital systems, where treatment decisions, diagnostics, and therapy onboarding occur in a coordinated workflow. Hospital pharmacies also manage cold-chain handling and prior-authorization processes for specialty therapies, which supports consistent dispensing. Even as specialty distribution and home delivery expand, hospitals remain a primary access point for starts, switches, and complex cases.

Axial Spondyloarthritis Market Drivers

Earlier diagnosis and expanding treated prevalence

Earlier identification of inflammatory back pain is increasing the number of patients who enter the treatment pathway before irreversible structural damage occurs. Wider use of imaging and improved clinical classification reduces diagnostic uncertainty, which supports faster referral to rheumatology care. As a result, more patients initiate disease-modifying therapy rather than relying solely on episodic symptom control. This expands treated prevalence across both radiographic and non-radiographic populations and increases long-term therapy duration per patient.

• For instance, Siemens Healthineers states that its Deep Resolve MRI technology can shorten brain MRI scan times by up to 70%, and the company has also highlighted a 3T knee MRI workflow reduced from about 10 minutes to under 2 minutes while maintaining diagnostic value, underscoring how faster high-quality imaging can help reduce diagnostic bottlenecks in inflammatory disease pathways.

Therapeutic innovation and broader mechanism choice

Newer targeted options and expanding biologic mechanisms are improving disease control in patients with inadequate response to first-line therapies. Clinicians now have greater ability to switch across mechanisms to manage persistent inflammation, which increases the likelihood of maintaining patients on active therapy. The growing range of options also supports treatment personalization based on comorbidities, tolerability, and patient preferences. This increases overall market value by sustaining demand across multiple therapy lines and supporting longer persistence on advanced agents.

• For instance, UCB reported in its Phase III BE MOBILE program that BIMZELX achieved ASAS40 at week 16 in 47.7% of non-radiographic axSpA patients (61/128) and 44.8% of radiographic axSpA patients (99/221), versus 21.4% (27/126) and 22.5% (25/111) with placebo, demonstrating how a newer IL-17A/IL-17F mechanism can broaden switching options beyond first-line therapy.

Payer coverage evolution and biosimilar-driven access expansion

Formulary decisions and step-therapy rules strongly influence treatment sequencing, but they also expand access as payers seek cost-efficient pathways. Biosimilars can reduce affordability barriers and increase uptake of biologic therapy among broader patient cohorts. Lower net pricing can encourage earlier initiation in appropriate patients and reduce discontinuation linked to cost burden. As coverage policies stabilize and competition increases, more patients are likely to enter biologic pathways, sustaining market expansion.

Convenience, adherence support, and shifting care delivery models

Patient preference for convenient therapy options is influencing route selection and persistence, especially for chronic inflammatory conditions requiring long-term management. Subcutaneous therapies supported by robust patient-assistance programs reduce friction in onboarding and refill continuity. At the same time, oral options appeal to patients who want fewer injections and less clinic dependency. Improvements in specialty pharmacy services, home delivery, and adherence tracking support continuity of care, which translates into sustained therapy revenues.

Axial Spondyloarthritis Market Challenges

Pricing pressure and reimbursement complexity remain persistent barriers, especially as more therapies compete in the same treatment lines. Payers often impose prior authorization, step edits, and switching requirements that can delay initiation and increase administrative burden for providers. These constraints can reduce speed to treatment optimization and may contribute to non-persistence if access interruptions occur. Cost containment also intensifies competition and can compress margins, particularly in markets with rapid biosimilar diffusion.

Clinical heterogeneity and diagnostic variability continue to limit consistent treatment pathways across regions and care settings. Patients can present with overlapping symptoms, delayed referrals, and uneven access to imaging, which can slow confirmation of disease and reduce timely escalation. Safety monitoring requirements for certain targeted therapies can also influence prescriber comfort and sequencing decisions. Together, these factors can create uneven uptake across segments and slow the pace of therapy intensification in under-resourced systems.

• For instance, GE HealthCare’s deep-learning AIR Recon DL reduced average MRI scan time by 40% to 50% across anatomies at Maçka EMAR and by about 50% for musculoskeletal imaging at Precision Imaging Center, illustrating how advanced imaging platforms can improve diagnostic throughput, even though uneven technology access still leaves pathway consistency fragmented across providers.

Axial Spondyloarthritis Market Trends and Opportunities

Oral targeted therapies are gaining attention as care systems emphasize convenience and long-term adherence. For some patients, oral regimens may reduce injection fatigue and improve continuation when disease control is achieved. This trend creates opportunity for differentiated positioning based on safety monitoring, tolerability, and real-world durability. As treatment algorithms mature, market growth can be supported by better segmentation of patients by response profile and comorbidity burden.

Digital health and specialty distribution models are becoming more important in chronic inflammatory disease management. Tele-rheumatology, home delivery, and structured adherence programs can reduce access friction and support continuity of therapy, particularly for biologics that require cold-chain handling and refill coordination. These models also help manage switching events driven by payer policies and improve patient education on administration. Over time, service-enabled distribution can become a key competitive lever alongside clinical differentiation.

• For instance, Evernorth’s Accredo Specialty Pharmacy supports rheumatoid arthritis and inflammatory conditions through digital tools such as refill-by-text, order tracking, and cold-chain delivery; across its specialty platform it reported 3.1 million clinical and compliance interactions in the last year, while its RA and inflammatory Therapeutic Resource Center model was associated with 12% fewer emergency room visits and 22% fewer inpatient admissions.

Regional Insights

North America (35.62% share, 2025)

North America leads revenue due to stronger diagnosis intensity, specialist availability, and established reimbursement pathways for advanced therapies. Higher treated prevalence and earlier escalation to disease-modifying regimens increase average revenue per patient. The region also benefits from mature specialty pharmacy infrastructure and patient-support programs that improve persistence. Competitive dynamics are shaped by payer-driven formulary management, which increases switching and heightens price competition across therapy classes.

Europe (28.14% share, 2025)

Europe holds a significant share supported by structured healthcare systems, concentrated rheumatology services, and broad availability of biologics in key markets. Many countries have well-defined treatment pathways, enabling consistent initiation and escalation after first-line failure. Pricing negotiations and biosimilar adoption pressure branded therapy value, but they also expand biologic access. Growth is reinforced by earlier diagnosis and steady penetration of newer mechanisms where reimbursement is secured.

Asia Pacific (24.11% share, 2025)

Asia Pacific growth is supported by large patient pools and improving diagnostic access, but revenue share reflects uneven reimbursement and affordability across countries. Expansion of tertiary care capacity and rising specialist availability in major urban centers improves treatment rates. As coverage frameworks evolve, biologic and targeted therapy uptake is expected to deepen, particularly in higher-income markets. Competitive opportunities are strongest in access expansion, patient support, and localized pricing strategies that broaden therapy eligibility.

Latin America (7.58% share, 2025)

Latin America remains smaller in value share due to affordability constraints and uneven availability of advanced therapies across public and private systems. Diagnosis and referral pathways can be inconsistent outside major metropolitan centers, delaying therapy initiation. Where reimbursement expands, biosimilars can drive increased biologic penetration. Growth is supported by improving healthcare access, but market development remains sensitive to currency dynamics and payer budgets.

Middle East & Africa (4.55% share, 2025)

Middle East & Africa represents the smallest share, shaped by uneven specialist density, variable imaging access, and heterogeneous reimbursement coverage. High-cost therapies tend to concentrate in private systems or higher-income markets where coverage frameworks are stronger. Public-sector constraints can limit uptake despite clinical need, creating variability between countries. Market expansion depends on strengthening rheumatology care pathways, widening reimbursement for specialty medicines, and improving diagnostic access in secondary cities.

Competitive Landscape

Competition is defined by portfolio breadth, mechanism differentiation, and the ability to secure favorable formulary positioning in an environment of rising price pressure. Companies compete on efficacy, safety monitoring requirements, dosing convenience, and long-term durability narratives that support switching and persistence. Lifecycle management, real-world evidence, and patient-support services are increasingly used to defend share, especially as biosimilars intensify price competition. Partnerships and label expansion strategies remain important as treatment sequencing evolves across radiographic and non-radiographic populations.

AbbVie Inc. competes through a combination of immunology portfolio depth and therapy sequencing relevance, supported by ongoing clinical evidence generation and access-focused contracting. The company’s approach typically emphasizes sustained disease control, differentiated patient selection, and strong specialty distribution capabilities. Competitive performance depends on aligning clinical positioning with payer policies that can mandate step therapy or switches. Continued investment in evidence, education, and patient support helps protect persistence and maintain utilization in long-term chronic disease management.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• AbbVie Inc.
• Novartis AG
• UCB S.A.
• Eli Lilly and Company
• Pfizer Inc.
• Johnson & Johnson
• Janssen Biotech
• Amgen Inc.
• Kyowa Kirin Co., Ltd.
• Bristol Myers Squibb / Celgene Corporation

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Recent Developments

• In June 2025, UCB announced that BIMZELX (bimekizumab-bkzx) showed three-year data at EULAR 2025 with lasting efficacy and control of inflammation in axial spondyloarthritis, strengthening its profile in the axSpA treatment landscape. The company said ASAS40 responses at three years were sustained in both non-radiographic axial spondyloarthritis and ankylosing spondylitis patients.
• In March 2024, AbbVie completed its USD 137.5 million acquisition of Landos Biopharma, adding the oral NLRX1 agonist NX-13 to its immunology pipeline. Industry coverage of the axial spondyloarthritis market highlighted this deal as a relevant competitive development in the broader inflammatory disease arena.
• In January 2025, MoonLake Immunotherapeutics announced that patient screening had started for three new sonelokimab trials, including a study in axial spondyloarthritis. The company said this expanded its clinical program into axSpA alongside existing studies in hidradenitis suppurativa and active psoriatic arthritis.

Report Scope

Segmentation

By Disease Type

• Radiographic Axial Spondyloarthritis / Ankylosing Spondylitis
• Non-radiographic Axial Spondyloarthritis

By Drug Class

• NSAIDs
• TNF Inhibitors
• IL-17 Inhibitors
• JAK Inhibitors
• Corticosteroids
• Conventional DMARDs / Other Therapies

By Route of Administration

• Oral
• Injectable / Subcutaneous
• Intravenous

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Earlier diagnosis and expanding treated prevalence

Advances in imaging and clearer clinical classification are enabling earlier identification of inflammatory back pain, allowing more patients to enter the treatment pathway before irreversible damage occurs. This increases the number of patients eligible for disease-modifying therapies and extends therapy duration.

Therapeutic innovation and broader mechanism choice

The introduction of new targeted therapies and biologics with diverse mechanisms of action is improving disease control for patients who do not respond to first-line treatments. This expands treatment options, supports personalized care, and sustains demand across multiple therapy lines.

Payer coverage evolution and biosimilar-driven access expansion

Wider adoption of biosimilars and evolving payer policies are reducing affordability barriers and increasing access to advanced therapies. This encourages earlier initiation of biologics and supports market growth by expanding the treated patient base.

Convenience, adherence support, and shifting care delivery models

Patient preference for convenient administration routes, such as subcutaneous injections and oral therapies, is driving therapy selection and persistence. Enhanced specialty pharmacy services, home delivery, and digital adherence programs further support long-term therapy continuity and market expansion.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.